Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

Sarepta Therapeutics is facing a challenging period after the deaths of two patients who received its Columbus-invented gene ...

The pharma company said it would lay off a third of its workforce and add a black-box warning to its controversial gene ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

The company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.

Shares of struggling drug developer Sarepta Therapeutics skyrocketed nearly 40% in extended trading Wednesday after the ...

The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene ...

The gene-therapy company is restructuring, laying off 36% of its workforce and making changes to its executive team.

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

After the market close on Wednesday, Sarepta Therapeutics introduced a strategic restructuring plan that involves focusing on high-value, high-impact programs and supporting long-term financials.

At the FDA's request, delandistrogene moxeparvovec (Elevidys), the only approved gene therapy for Duchenne muscular dystrophy ...

Sarepta Therapeutics said it will eliminate 36% of its workforce—approximately 500 jobs—in a restructuring that follows the ...